interpretierte, ging es zuvorderst um Novavax, die Zulassung in Korea und den Start der Produktion durch SK. Pfizer und Moderna lediglich untergeordnet... Eigentlich erwarte ich heute einen tüchtigen Schub! Mal schauen...
Novavax volunteers in UK threaten to quit over approval delays
... He said that in a Facebook group of Novavax participants, many were “contacting the Covid centres and having another vaccine” – without “informing them that they have participated in the Novavax trial”.
... Volunteers were advised not to seek an alternative vaccine. The gap between two doses of vaccine is 12 weeks in the UK.
... Novavax will not file for approval of its Covid-19 vaccine until July at the earliest, due to manufacturing issues related to an assay needed to show regulators its vaccine manufacturing process is consistent across different sites.
... On its website, the National Institute for Health Research said it did not want people to feel “disadvantaged”. It said: “As you are aware from the media, plans are under way to recognise vaccine status and have it displayed on the NHS app.”
It added: “The government is working at speed to make sure that records for trial participants are transferred to the data systems the NHS app uses to demonstrate vaccine status. This is expected to be in place by the time the government next reviews entry requirements.”
... Samsung Biologics CEO John Rim, SK Bioscience CEO Ahn Jae-yong and Novavax CEO Stanley Erck were present at the meeting.
According to media reports, Samsung Biologics is in talks with Moderna to manufacture the U.S. drug maker's vaccine in Korea, while SK Bioscience is seeking to extend its licensing deal with Novavax for the NVX-CoV2373 coronavirus vaccine through next year.
Novavax Statement on Participation in Mix-and-Match COVID-19 Vaccine Booster Trial in the United Kingdom May 21, 2021 at 2:25 PM EDT
Novavax is participating in a mix-and-match (vaccine interchangeability) COVID-19 vaccine booster trial that is being led by the University Hospital Southampton NHS Foundation Trust and other UK National Institute for Health Research (NIHR) sites. Novavax' recombinant protein vaccine candidate, NVX-CoV2373, is one of seven COVID-19 vaccines that will be studied to evaluate the potential for providing a booster dose from different manufacturers in people who have previously received two doses of an authorized vaccine. This study will assess the safety and immune response against COVID-19 provided by these various vaccine schedules. The study will begin during the first week of June and is receiving support from the UK government Vaccines Task Force (VTF) and Department of Health and Social Care (DHSC).
Rachel King, 700 Stück zu $139.64! Nicht viel aber ein gutes Zeichen. Sie und NanoFlu waren damals (2019) der Anlass für mich zu kaufen, dann kam der R/S und der Hype begann.
Warum ich nicht verkaufte. Anschließend ging es eh ab...Der Kauf von Rachel King ist zumindest ein Statement in die Firma, wenn auch ein kleines. Ich hatte mir von dem Meeting Biden/Moon samt Entourage mehr versprochen, evtl arbeitet man noch an Feinheiten vor der Verkündung irgendwelcher Agreements..?
Wir brauchen die Zulassung, in irgendeinem verdammten Land, damit der Bock endlich umgestoßen wird! Solange das nicht passiert, enteilen uns die Anderen immer weiter und schnappen sich die fetten Deals!
richtig, NanoFlu im Vergleich mit Fluzone von Sanofi. Ja ein approval muss dringend her, denn Pfizer und Moderna spielen nun auch bei COVAX eine bedeutende Rolle.
... Moving forward, expect the company to try to fold its successful coronavirus vaccine and its successful influenza vaccine into one unified jab. Investors might need to wait a few years for the combination to hit the market, given that it's only in preclinical studies at the moment. Nonetheless, the convenience of such a product could make it a best-seller -- and that's why it's worth buying the stock today, before the market has had a chance to price in the expected revenue.
US-Impfstoffe werden künftig auch in Südkorea hergestellt Die US-Konzerne Moderna und Novavax wollen ihren Impfstoff künftig auch in Südkorea herstellen. Beide Unternehmen einigen sich mit der Regierung in Seoul auf ein entsprechendes Abkommen. Der südkoreanische Präsident Moon Jae-in steht unter Druck, Impfstoff schneller im Land verfügbar zu haben. Am Freitag hatten Moon und US-Präsident Joe Biden eine umfassende Partnerschaft beider Länder für Covid-19-Impfstoffe abgeschlossen.
Dr. Glenn will discuss NVX-CoV2373, including analysis of the safety, efficacy and immunogenicity data to-date"
Presentation details are as follows: Date: Tuesday, May 25, 2021 Time: 9:50 a.m. – 10:30 a.m. Eastern Time (ET) Presentation title: Recombinant Protein COVID-19 Vaccine Update Presenter: Gregory M. Glenn, M.D. This event is open to the public. Register at: isvcongress.org/default.php https://www.isvcongress.org/default.php
Novavax ist nur noch unter "ferner liefen" dabei. Biontech und Moderna haben das Rennen gemacht. Wenn wir weitere Vakzine brauchen, werden wir einen Markt mit mehreren Anbietern und riesigen Kapazitäten sehen, auf der anderen Seiten Staaten die en gros Vakzine bestellen. Der Preis wird hierbei das wichtigste Kriterium sein.
Das Novavax weltweit Kapazitäten zur Verfügung hat um große Mengen zu produzieren, sowie in Sachen Preis und Lagerdauer weit vorne liegt. Mir ist auch in Bezug darauf nicht bange
SII has a tie-up with US' Novavax to manufacture and supply Covovax vaccine in India and in low- and middle-income countries as part of the COVAX vaccine alliance countries.
New Delhi: The Modi government has given the go-ahead to vaccine producer Serum Institute of India (SII) to manufacture and stockpile Covovax vaccine, ThePrint has learnt.
SII has already begun the production of the vaccine that is being developed in partnership with the US vaccine maker, Novavax.
SII has a tie-up with Novavax to manufacture and supply the vaccine in India and in low- and middle-income countries as part of the COVAX vaccine alliance countries.
“The government has given the nod to SII to start manufacturing Covovax. It will be buying the entire quantity that SII has started stockpiling,” an industry source privy to the developments told ThePrint.
The move is triggered by the severe shortage of vaccines that has put on halt the vaccination drive in several states in India. The Modi government is scrambling to find more options that could help in accelerating the country’s inoculation drive.
Three vaccines which are currently approved for use by the drug regulator, the Drug Controller General of India (DCGI) are Covishield, Covaxin, and Russia’s Sputnik V. The central government is also in talks with US pharma companies Pfizer and Moderna.
ThePrint reached the official spokesperson of SII and Rajesh Bhushan, secretary, Ministry of Health and Family Welfare, via text messages, for an official comment but did not receive any response till the time of publishing.
1) United States & Australian data is excellent - very high antibody levels in the US trials. 2) We may be the Last clinical trial in the US (for covid vaccines). Many thought we could not complete it, but it is completed now and we have the data. We unblind in a few days. 3) The Hallmark of our vaccine is Safety - just mostly 'mild' and some 'moderate' side effects, and not severe. We are the safest vaccine. 4) As a booster, Novavax creates an 'etremely high' immunity to covid19. 5) On approval - Dr. Glenn says "I don't see anymore glitches. None." 6) Dr. Glenn "Next year, you will look back to this, and we will be a big success story."
Der Zug ist nicht nur abgefahren, er ist zwei Stationen weiter... Nach wie vor kann Novavax in der EU nicht produzieren. Novavax ist bei der Produktion auf Filtersysteme angewiesen, die nur in den USA produziert werden. Nach wie vor gibt es von der US Regierung eine Exportverbot nach dem Motto "America first". Der Umstieg auf andere Systeme ist in der Pharma aus regulatorischen Gründen nur sehr zeitaufwendig möglich.
Ging mir ähnlich, allerdings wurden ja die Ergebnisse von der FDA und EMA, ect unter die Lupe genommen und für gut, bzw sehr gut befunden. Gleich mehrere fachspezifische Organisationen zu täuschen halte ich für ausgeschlossen
Thread abonnieren
